2,687,500 Shares CAPRICOR THERAPEUTICS, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 16th, 2016 • Capricor Therapeutics, Inc. • Pharmaceutical preparations • New York
Capricor Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 2,687,500 shares (the “Firm Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 403,125 shares (the “Option Shares”) of Common Stock from the Company for the purpose of covering over-allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are collectively called the “Shares.”
SUBSCRIPTION AGREEMENTSubscription Agreement • September 16th, 2016 • Capricor Therapeutics, Inc. • Pharmaceutical preparations
This Subscription Agreement (this “Subscription”) is dated as of September 16, 2016, by and between Capricor Therapeutics, Inc., a Delaware corporation (the “Company”), and Cedars-Sinai Medical Center (the “Investor”).
